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The mechanism ofaction ofthecancer chemotherapeutic agents (alkylating agents,
antimetabolites, antibiotics, plant alkaloids, enzymes, and hormones) is thought to
be the blocking of cancer growth and cell division, with the exception oflow-dose
cyclophosphamide, which seems toinhibit suppression ofimmune responses against
cancer cells (1, 2). In general, these anticancer drugs inhibit immune functions, in-
cludingnatural cell-mediated cytotoxicity (3). On the other hand, combined cancer
chemotherapeutic agents instead ofa single agent are frequently used and they are
usually administered in several cycles to cancer-bearing patients. The mechanism
ofaction ofthiscombined chemotherapy is alsothought tobe the blockingofcancer
cell growth and cell division. The effect ofcombined cancer chemotherapeutic agents
on natural killing has not been examined extensively.
From the experiments ofexamining NK activity against K562 human myeloge-
nous leukemia cells and killer activity against NK-resistant B cell lymphoma Raji
cellsduring MVAC (methotrexate, vinblastin, adriamycin, andcis-platin) combined
chemotherapy (4) in bladdercancer patients, wefoundthe appearance ofvery strong
lytic activity against NK-resistant Raji cells in the peripheral blood after til mo
of each cycle of therapy. The target spectrum of this killing was wide. mAbs and
complement treatment revealed that the effector cells express CD8 and SLl pheno-
type weakly, but do not express CD4, CD5, CD16, Leu-7, or OKM1, suggesting
that these effector cells are lymphokine activated killer (LAK)-like cells. Examina-
tions are now under way with other protocols ofcancer chemotherapy, but up to
now, MVAC for bladder cancer or ureter cancer, PEB (cis-platin, etoposide, and
bleomycin) (5) fortesticular cancer, and MA (methotrexate, adriamycin) fortestic-
ularcancer, which are all we have examined, induced this strong LAK-like activity
in the peripheral blood.
Materials and Methods
Patients.
￿
Among the six bladder tumorpatients and twotesticular tumor patients whose
cytotoxic activities during chemotherapy we have monitored, four bladder tumor patients
and one testicular tumor patient were chosen to show in Fig. 1.
Treatment.
￿
Fromday 7 to 11, bladdertumor patients got 2,000radpreoperational irradia-
tion. On day 14, totalcystectomywasperformed. Two orthree cycles ofMVAC chemotherapy
were performed with 1-mo intervals starting on day 27. Each MVAC cycle consisted of2 d
ofintravenous injection (1 mg/kg ofmethotrexate on day 1 and 0.1 mg/kg ofvinblastin, 1
mg/kg ofadriamycin, and 2 mg/kg ofcis-platin on day 2). For testicular tumor patients, two
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cycles ofPEB chemotherapy without prior radiation were administered. Each PEB cycle con-
sisted of an intravenous injection of 1 mg/kg ofcis-plastn, 2 mg/kg ofetoposide, and 0.2 mg/kg
of bleomycin per day for 3 d.
Elector Cells.
￿
PBL were isolated as effector cells from the carbonyl iron-treated blood
of these patients by separation on Ficoll-Hypaque gradients. Adherent cells were removed
by a 1-h, 37 °C incubation on plastic dishes precoated with autologous plasma.
Target Cells.
￿
The cell linesused in this study included human B cell lymphoma Raji cells,
erythroleukemia K562 cells, bladder tumor T-24 cells, prostatic cancer PC-3 cells, murine
lymphoma YAC cells, UVinduced fibrosarcoma UV female 1, and mammary carcinoma
MM2.
Cytotoxicity Assay.
￿
A cytotoxicity assay was performed by a standard "Cr-release assay
as described (6). LU were calculated from cytotoxic titration curves; 1 LU was defined as
the number of effector cells required to cause 20% lysis of 5 x 103 targets. The data are
presented as LU/10' effector cells.
Negative Selection ofLymphocyte Populations.
￿
Monoclonal anti-Leu-7 (FINK-1), anti-Leu-11B
(CD16), anti-Leu-3A (CD4), and anti-Leu-1 (CD5) antibodies were obtained from Becton
Dickinson & Co. (Mountain View, CA). Monoclonal antiT8 (CD8) antibody was purchased
from Coulter Electronics, Inc. (Hialeah, FL). Monoclonal SL-1 antibody is an anti-human
pan T cell antibody and was obtained from Ortho Diagnostic Systems Inc. (Tokyo, Japan).
This antibody can stain 100% of peripheral T cells and <5 0 1o of peripheral B cells and bone
marrow cells (7). Effector cells were treated with mAbs for 30 min at 4°C and aftercentrifu-
gation the supernatant was discarded and the young rabbit complementobtained from Pel-
Freeze Biologicals (Rogers, AR) was added and incubated for 40 min at 37°C. After washing
three times, antibody-treated effector cells were assayed for cytotoxicity and aliquots were
used for assuring phenotypes by FAGS staining.
Results
We first planned experiments for assaying NK and killer activity against NK-
resistant targets in order to determine the optimal timing of adding biological re-
sponse modifiers (BRM) to usual chemotherapy. Hence, we assayed these two types
of killer activity once a week during all the courses of treatment. As shown in Fig.
1 A, before irradiation, NK activity was comparatively high but killer activity against
NK-resistant Raji cells was as minimal and negligible as that of normal persons (20
t 4 LU from 25 normal volunteers and <1 LU from 10 bladder tumor-bearing
patients before therapy) and a first peak of killer activity against NK-resistant Raji
cells appeared after radiation. After the first course of MVAC and PEB therapy (as
before radiation), we could see no killer activity against Raji cells until the burst
appearance of this activity after -30 d. Without further chemotherapy no more peaks
were seen (data not shown). And -30 d after the second or third chemotherapy,
we could always (all of the bladder and testicular tumor patients we examined) see
the second or third peak of this killer activity. These results show that appearance
ofthese potent killing activities against NK-resistant target cells was induced by MVAC
or PEB combination chemotherapy.
To know what component of combined chemotherapeutic agents is responsible
for this killer induction in peripheral blood, we further assayed this killer activity
of testicular tumor-bearing patients who were treated with different combined
chemotherapeutic agents MA. MA also induced this killer activity after N1 mo of
chemotherapy (data not shown). From these results, no special chemotherapeutic
agents, but some kinds of changes (e.g., bone marrow suppression and regenera-
tion) common to these combinations, were thought to induce this killer activity.
NK activity during MVAC chemotherapy had the same tendency as this killerKIYOHARA ET AL.
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FIGURE 1.
￿
LAK-like killer and
NK activity duringchemother-
apies. (") LAK like killer ac-
tivity against Raji cells; (O) NK
activity against K562 cells.
Bladder tumor patients treated
with MVAC (A-D). A testicular
tumor patient treated with PEB
activity against NK-resistant target cells. To characterize this killer activity, first,
we used various tumor cells as target cells (Table I). These killer cells could lyse
not only NK-resistant Raji cells and NK-sensitive K562 cells but also abroad spec-
trum of target cells, including human bladder tumor T-24 cells, human prostatic
cancer PC-3 cells, andmurine fibrosarcoma UV female 1 cells. This showsthat these
killer cells can recognize and lyse without restriction. Target specificity of MVAC-
induced killer activity, PEB-induced killer activity, and LAK cells induced in vitro
were quite similar. Phenotypes of these chemotherapy-induced killer cells were ex-
amined using mAbs and complement treatment (negative selection). As shown in
Table II, HNK-1 or CD16 treatmentdid not influence this killer activity at all, though
HNK-1+ or CD16+ cells in the treated preparation were only 2% or 3% of original
TABLE I
Target Spectrum ofMVAC-induced Killer Cells, PEB-induced Killer Cells,
NK Cells, and LAK Cells
` Results are expressed as LU calculated from cytotoxic titration curves of an 18-h 51Cr-release assay.
: PBL from a normal volunteer were cultured in 10 U/ml ofhuman rIL-2 for 5 d and the cytotoxic activity
was assayed by an 18-h 51Cr-release assay.
51Cr-labeled target cells
Killer cells Raji Daudi YAC T-24 PC-3 K562 UV 1 MM2
MVAC-induced killer 460` 640 73 160 222 492 221 0
PEB-induced killer 446 800 400 320 337 1280 356 0
NK 0 0 0 0 0 376 0 0
LAK: 100 ND 246 397 ND 376 ND 02358
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TABLE II
Phenotypic Characteristics of MYAC-induced Killer Cells
' Results are expressed as LU calculated from cytotoxic titration curves of an
18-h S'Cr-release assay.
population by FAGS (data not shown). Among T cell markers, only SL-1 and CD8
were thought tobe weakly present on thesechemotherapy-inducedkiller cells. Hence,
the effector cells were thought to be CD4- , CD5-, CD16- , Leu-7- , OKMl - , and
CD8 weakly positive SL-1 weakly positive LAK-like cells.
Discussion
We found LAK-like cell induction in the peripheral blood after administration
ofanticancer drugs. Perhaps this is the first report ofthe presence of in vivo acti-
vated LAK cells without any administration of IL-2.
From the results that MVAC, as well as the PEB or MA combination, equally
induced LAK-like activity at ti1 mo after administration, we think that this LAK-
like cell induction is not due to specific drug actions but due to some common
phenomenon, for example, regeneration from myelosuppression among these
chemotherapeutic agents. Indeed, weusually couldseemildorsevere lymphocytopenia
2 wkafterchemotherapy andrecovery from it N1-2 wklater. But, how itregenerates
is one ofthe important questions to be solved in the future. As it is reported with
IL-2 and IL-3, hematopoietic progenitor cellcoloniescould bedirectly differentiated
into large granular lymphocytes (LGL) (8), which are known to be activated into
LAK cells (9, 10), it seems possible that IL-2 or IL-3 may also play some roles to
generate this chemotherapy-induced LAK-like cell activity, though these effectors
are T cells instead ofbeing LGL. In the murine system, it is reported that after
a sublethal dose ofcyclophosphamide administration, all ofthe killer cell activities
(LAK, NK, CTL) were abolished at once. Andrecovery wasin the orderofallogeneic
CTL, NK, LAK (11-13). In these reports, however, a sublethaldoseofcyclophospha-
midedid not induce LAKactivity but the precursors ofLAKcells reappeared after
regeneration. Theseprecursors couldbe activated afterincubation withIL-2 invitro.
The situation is the same in the case ofmurine bone marrow chimeras (14). The
difference is that in our experiments LAK-like effector cells, instead of precursor
cells, were induced after chemotherapy. Andthisis the reason we couldnot perform
positive selection for surface phenotype determination.
Kinetics ofkilling revealed that from 4 h, we could see cytolysis, and in 18-24 h,
Treatment Lytic activity`
Percent reduction of
lytic activity
after treatment
No Ab 388 -
Leu-7 (HNK-1) 400 0
Leu-11B (CD16) 390 0
Leu-7 + Leu-11B 388 0
Leu-3A (CD4) 427 0
Leu-1 (CD5) 356 8
OKT8 (CD8) 333 14
OKMI 397 0
SL-1 246 36KIYOHARA ET AL.
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it reaches a plateau (data not shown). The magnitude ofkilling is very high (at least
>500 LU and sometimes >1,000 LU) and the duration is comparatively long (N2
wk). From this potent lytic activity, we think that these LAK-like cells may play
some role in destroying tumor cells resistant to chemotherapy, because some kinds
of chemoresistant murine or human tumor cells are reported to be more sensitive
to LAK cells (15). But the real role of these chemotherapy-induced LAK-like cells
is still obscure and experiments are now under way to clarify it.
Summary
Natural cell-mediated cytotoxicity against NK-resistant target tumor cells was found
in the peripheral blood of tumor-bearing patients tit mo after combined chemo-
therapy. The recognition specificity of these effector cells was broad and had no re-
striction. From the experiments ofnegative selection with mAbs and complements,
these newly developed killer cells after chemotherapy were thought to be LAK-like
cells. Contribution of these LAK-like cells to the mechanism of action of anticancer
drugs remains to be clarified.
Receivedfor publication 6July 1988 and in revisedform 10 August 1988.
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